News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,150 Results
Type
Article (40826)
Company Profile (289)
Press Release (668035)
Multimedia
Podcasts (50)
Webinars (12)
Section
Business (206917)
Career Advice (2049)
Deals (35736)
Drug Delivery (98)
Drug Development (81913)
Employer Resources (174)
FDA (16227)
Job Trends (15038)
News (349289)
Policy (32831)
Tag
Academia (2583)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (50320)
ALS (92)
Alzheimer's disease (1390)
Antibody-drug conjugate (ADC) (126)
Approvals (16233)
Artificial intelligence (259)
Autoimmune disease (21)
Automation (16)
Bankruptcy (363)
Best Places to Work (11706)
BIOSECURE Act (20)
Biosimilars (106)
Biotechnology (213)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (279)
Cancer (2278)
Cardiovascular disease (174)
Career advice (1714)
Career pathing (30)
CAR-T (154)
Cell therapy (433)
Cervical cancer (19)
Clinical research (66652)
Collaboration (849)
Company closure (1)
Compensation (534)
Complete response letters (19)
COVID-19 (2615)
CRISPR (42)
C-suite (247)
Cystic fibrosis (100)
Data (2222)
Decentralized trials (2)
Denatured (18)
Depression (45)
Diabetes (271)
Diagnostics (6404)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (87150)
Editorial (39)
Employer branding (21)
Employer resources (148)
Events (115292)
Executive appointments (734)
FDA (17499)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (760)
Gene editing (106)
Generative AI (21)
Gene therapy (311)
GLP-1 (714)
Government (4441)
Grass and pollen (4)
Guidances (67)
Healthcare (18912)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (30)
Infectious disease (2758)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (99)
Interviews (315)
IPO (16621)
IRA (40)
Job creations (3746)
Job search strategy (1458)
Kidney cancer (10)
Labor market (38)
Layoffs (470)
Leadership (17)
Legal (7984)
Liver cancer (75)
Lung cancer (321)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (313)
MASH (67)
Medical device (13398)
Medtech (13403)
Mergers & acquisitions (19658)
Metabolic disorders (692)
Multiple sclerosis (81)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1933)
NextGen: Class of 2025 (6584)
Non-profit (4511)
Now hiring (39)
Obesity (368)
Opinion (216)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (84)
Parkinson's disease (149)
Partnered (21)
Patents (236)
Patient recruitment (113)
Peanut (47)
People (58356)
Pharmaceutical (68)
Pharmacy benefit managers (18)
Phase I (20840)
Phase II (29396)
Phase III (21752)
Pipeline (1207)
Policy (140)
Postmarket research (2572)
Preclinical (8881)
Press Release (71)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (248)
Rare diseases (383)
Real estate (6072)
Recruiting (67)
Regulatory (22486)
Reports (46)
Research institute (2352)
Resumes & cover letters (354)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (131)
Series B (88)
Service/supplier (11)
Sickle cell disease (54)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3684)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (30)
Vaccines (692)
Venture capitalists (42)
Weight loss (239)
Women's health (35)
Worklife (16)
Date
Today (143)
Last 7 days (907)
Last 30 days (2629)
Last 365 days (33169)
2025 (10846)
2024 (35641)
2023 (40431)
2022 (51639)
2021 (56111)
2020 (54482)
2019 (46912)
2018 (35351)
2017 (32529)
2016 (32054)
2015 (38032)
2014 (31812)
2013 (26849)
2012 (29165)
2011 (29835)
2010 (27936)
Location
Africa (749)
Alabama (53)
Alaska (7)
Arizona (235)
Arkansas (13)
Asia (38792)
Australia (6471)
California (6192)
Canada (2018)
China (531)
Colorado (268)
Connecticut (279)
Delaware (150)
Europe (83923)
Florida (912)
Georgia (207)
Idaho (57)
Illinois (563)
India (25)
Indiana (308)
Iowa (11)
Japan (164)
Kansas (108)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (901)
Massachusetts (4641)
Michigan (221)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (30)
Nebraska (25)
Nevada (63)
New Hampshire (64)
New Jersey (1748)
New Mexico (29)
New York (1758)
North Carolina (993)
North Dakota (8)
Northern California (2707)
Ohio (205)
Oklahoma (14)
Oregon (34)
Pennsylvania (1389)
Puerto Rico (12)
Rhode Island (33)
South America (1138)
South Carolina (23)
South Dakota (1)
Southern California (2322)
Tennessee (101)
Texas (915)
United States (23396)
Utah (183)
Virginia (148)
Washington D.C. (61)
Washington State (560)
West Virginia (3)
Wisconsin (55)
709,150 Results for "refuge biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
April 30, 2025
·
3 min read
Press Releases
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 23, 2025
·
6 min read
Business
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (“Refuge”), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.
October 20, 2022
·
5 min read
Press Releases
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 7, 2025
·
8 min read
Press Releases
CorMedix Inc. Added to Nasdaq Biotechnology Index
December 20, 2024
·
1 min read
Press Releases
Adnexus Biotechnologies Inc. Unveils AI-Driven Malaria Cure with Trapicolast
January 7, 2025
·
4 min read
Deals
Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.
Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.
March 20, 2024
·
2 min read
Business
Kite Gains Access to Refuge’s Gene Expression Platform in Licensing Deal
Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter’s propriety gene expression plaform and develop potential blood cancer therapies.
October 21, 2022
·
2 min read
·
Mark Terry
Press Releases
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
May 2, 2025
·
3 min read
Business
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
7 min read
1 of 70,915
Next
